drugset / Trial / NCT02245945

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945

Phase 1 Withdrawn CONRAD
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this trial is to assess the safety and acceptability of Tenofovir (TFV) 1% gel in adolescent females over 12 weeks of a minimum of twice weekly dosing following the BAT24 regimen.

Timeline

Start
Primary completion
2015-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Small molecule 4 ml Other

Indications

No indication recorded.